
Quarterly Result12 Nov 2026, 01:03 pm
Kwality Pharma: Unaudited Q2 FY27 Results Approved
AI Summary
Kwality Pharmaceuticals Ltd. announced the approval of its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board of Directors also accepted the resignation of M/s. Vijay Mehra & Co. as Statutory Auditors and approved the appointment of M/s. B S R & Co. LLP to fill the casual vacancy, subject to shareholder approval. The company reported strong performance in Q2 FY27 with consolidated revenue growth of 63% year-on-year and PAT doubling.
Key Highlights
- Unaudited financial results for Q2 and H1 FY27 approved.
- Resignation of Statutory Auditors M/s. Vijay Mehra & Co. noted.
- M/s. B S R & Co. LLP appointed as new Statutory Auditors.
- Appointment subject to shareholder approval at a General Meeting.
- Company reported strong Q2 FY27 performance with significant revenue growth.
Price Impact
More from KPL